AU1521000A - Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye - Google Patents

Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye

Info

Publication number
AU1521000A
AU1521000A AU15210/00A AU1521000A AU1521000A AU 1521000 A AU1521000 A AU 1521000A AU 15210/00 A AU15210/00 A AU 15210/00A AU 1521000 A AU1521000 A AU 1521000A AU 1521000 A AU1521000 A AU 1521000A
Authority
AU
Australia
Prior art keywords
stnfri
prophylaxis
disorders
eye
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15210/00A
Inventor
M. Reza Dana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc filed Critical Schepens Eye Research Institute Inc
Publication of AU1521000A publication Critical patent/AU1521000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU15210/00A 1998-11-06 1999-11-05 Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye Abandoned AU1521000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10735198P 1998-11-06 1998-11-06
US60107351 1998-11-06
PCT/US1999/026262 WO2000027421A2 (en) 1998-11-06 1999-11-05 LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE

Publications (1)

Publication Number Publication Date
AU1521000A true AU1521000A (en) 2000-05-29

Family

ID=22316208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15210/00A Abandoned AU1521000A (en) 1998-11-06 1999-11-05 Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye

Country Status (2)

Country Link
AU (1) AU1521000A (en)
WO (1) WO2000027421A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US20090028850A1 (en) 2004-05-14 2009-01-29 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
RS53864B1 (en) 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
PL2018426T3 (en) 2006-05-19 2013-10-31 Alcon Res Ltd Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
US20090098136A1 (en) * 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
SI2915529T1 (en) 2008-05-07 2017-09-29 The Regents Of The University Of California Therapeutic replenishment and enrichment of ocular surface lubrication
JP6150734B2 (en) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド Use of anti-CD200 antibodies to prolong allograft survival
KR101514238B1 (en) 2012-06-21 2015-04-28 한올바이오파마주식회사 A novel use of modified human tumor necrosis factor receptor-1
US20160184391A1 (en) 2013-08-16 2016-06-30 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5696198A (en) * 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases

Also Published As

Publication number Publication date
WO2000027421A2 (en) 2000-05-18
WO2000027421A3 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
AU1633400A (en) Systems and methods for electrosurgical treatment of vascular disorders
WO2002060955A3 (en) Modified antibodies and methods of use
WO2002067810A3 (en) Adjustable bone protheses and related methods
AU5654094A (en) Application of riluzole in the treatment of neurological lesions related to traumatic injuries
NO992755D0 (en) Prosthesis of the tendon's retina for the treatment of presbyopia and other disorders of the eyes
EP1143956A3 (en) Compositions and methods for the treatment of anorectal disorders
WO2000038663A3 (en) Ep4 receptor agonists for treatment of dry eye
BE2014C028I2 (en)
PL352229A1 (en) Prosthesis of sclera for treatment of presbyopia and other sight disorders
AU4340199A (en) Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma
AU6391700A (en) Vascular device for emboli, thrombus and foreign body removal and methods of use
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
IL158775A0 (en) Use of an antioxidant for treating and or preventing surface ocular disorders
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU2002307430A1 (en) Method and system for photodisruption of tissue of the eye
AU1521000A (en) Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
WO2000018387A3 (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU3965497A (en) Methods of treatment of eye trauma and disorders
AU9065291A (en) Use of angiotensin ii receptor antagonists in the treatment of macular degeneration
AU2693697A (en) Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin
AU2182800A (en) Use of inhibitors of gag synthesis for the treatment of corneal haze

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase